ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Apr 2, 2018
Why Some Investors Fail -- Worms!
Image Source: crabchick. When you read our research, we’re not just providing financial metrics -- Valuentum is striving to provide an answer to the most important question in investing: what is a company worth? Though there are varying opinions about which underlying factor is the most important investment consideration, at the end of the day, the process of valuation collects every investment consideration to provide a conclusion. It is the answer after all other considerations, the final outcome of analysis. It is why we say that investors that don't pay attention to valuation may be doomed to fail...eventually. Not seeking valuation is not seeking the answer.
Mar 30, 2018
Dividend Increases/Decreases for the Week Ending March 30
Let's take a look at companies that raised/lowered their dividend this week.
Mar 29, 2018
Verint’s Big Move Puts It Ahead of the Market
We think Verint Systems is getting a bad rap about its non-GAAP reporting. Operating cash flow at the company is tremendous, and the market may finally be coming around to recognizing its undervalued nature.
Mar 29, 2018
Dividend Highlights in Big Pharma
The first quarter of 2018 will go down in the record books as one of the most volatile in recent memory--a sharp jump out of the gate was met with significant selling at the end of March as numerous political and economic worries entered the picture. We believe a timely review of some of the dividend stalwarts is in order.
Mar 28, 2018
PCSK9 Woes Weigh on Amgen and Regeneron
Image shown: Amgen and Regeneron have both meaningfully trailed the market since October of 2017. The robustness of the clinical pipeline offers an important clue regarding the health and vitality of a biotech/pharma company, as the clinical pipeline is critical towards maintaining and growing the top line. One of the most promising, and dare-we-say, overhyped new treatments to enter the market is the PCSK9 cholesterol-lowering agents, with Amgen and Regeneron leading the pack. Let’s discuss the results of Regeneron’s treatment along with a discussion of the path forward for the treatment.
Mar 27, 2018
Tesla’s Shares Get Hammered
Tesla’s shares have been overpriced for some time, but the Valuentum Buying Index system didn’t raise a big red flag until mid-June of last year. Shares have been getting hammered.
Mar 27, 2018
Value Investors Starting to Salivate Over Facebook’s Fall
Image Source: DonkeyHotey. Facebook is becoming a value investor’s dream: a stock with fantastic free cash flow generation and balance sheet health dealing with transient headline noise. We’re waiting for shares to start to turn upward before we would consider adding to the hypothetical weighting in the simulated Best Ideas Newsletter portfolio. They look cheap!
Mar 26, 2018
Ongoing Optimization To Maximize The Value
We continue to help readers find some of our best ideas for consideration, and companies in the Diagnostic Substances industry weren't well-traveled by our readership. We’re allocating resources to better and more compelling opportunities that maximize the value of your membership. Please be sure to access the simulated newsletter portfolios for our best ideas!
Mar 24, 2018
Archive: Nelson's "Off the Cuff" Video Series
Image: President of Investment Research Brian Nelson. We hope you enjoyed the "Off the Cuff" video series, where President of Investment Research at Valuentum Brian Nelson talked in front of the camera for about 10 minutes each episode! The videos were purposely designed to be low-tech, we know - we call this "authen-tech." We like that, and you should, too. These are not instructional videos. They are meant to be energetic, exciting, and a bit controversial. Nelson tells it how it is. That's the only way. Videos filmed December and January 2017/2018. Follow up reading/videos provided.
Mar 23, 2018
Dividend Increases/Decreases for the Week Ending March 23
Let's take a look at companies that raised/lowered their dividend this week.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.